PMID- 10708707
OWN - NLM
STAT- MEDLINE
DCOM- 20000511
LR  - 20191210
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 390
IP  - 1-2
DP  - 2000 Feb 25
TI  - Activation of p38 mitogen-activated protein kinase by 
      formyl-methionyl-leucyl-phenylalanine in rat neutrophils.
PG  - 61-6
AB  - The signaling pathways leading to p38 mitogen-activated protein kinase (MAPK) 
      activation in formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated rat 
      neutrophils were examined. Immunoblot analysis with antibodies against a 
      phosphorylated form of p38 MAPK showed that fMLP-stimulated p38 MAPK activation 
      was dependent on a pertussis toxin-sensitive G protein. Two phosphatidylinositol 
      3-kinase inhibitors, wortmannin and 
      2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), did not affect the 
      p38 MAPK activation. Phosphorylation of p38 MAPK was concentration dependently 
      attenuated by a tyrosine kinase inhibitor, genistein, and by a Ca(2+)-dependent 
      protein kinase C inhibitor, 
      13-cyanoethyl-12-methyl-6,7,12,13-tetrahydroindolo[2,3-a]pyrrolo[3 , 
      4-c]carbazole-7-one (Go6976). However, the protein kinase C inhibitors with a 
      broader spectrum, 
      2-[1-(3-dimethylaminopropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-y 
      l)-maleimide (Go6983) and 
      2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimi de 
      (GF109203X), had no inhibitory effect. fMLP-stimulated p38 MAPK phosphorylation 
      was also reduced in cells pretreated with a phospholipase C inhibitor, 
      1-[6-((17beta-3-methoxyestra-1,3, 
      5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione (U73122), or preloaded with 
      an intracellular Ca(2+) chelator, 1, 
      2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (BAPTA). We conclude 
      that phosphorylation of p38 MAPK by fMLP stimulation in rat neutrophils is 
      dependent on G(i/o) protein, nonreceptor tyrosine kinase, phospholipase C/Ca(2+), 
      and probably Ca(2+)-dependent protein kinase C pathways.
FAU - Chang, L C
AU  - Chang LC
AD  - Department of Education and Research, Taichung Veterans General Hospital, 
      Taichung, Taiwan.
FAU - Wang, J P
AU  - Wang JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Chelating Agents)
RN  - 0 (Enzyme Activators)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinase Type 1)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.17 (Camk1 protein, rat)
RN  - EC 2.7.11.17 (Pnck protein, rat)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - EC 3.1.4.- (Type C Phospholipases)
RN  - EC 3.6.1.- (GTP-Binding Proteins)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Calcium-Calmodulin-Dependent Protein Kinase Type 1
MH  - Calcium-Calmodulin-Dependent Protein Kinases/metabolism
MH  - Chelating Agents/pharmacology
MH  - Enzyme Activation/drug effects
MH  - Enzyme Activators/*pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - GTP-Binding Proteins/metabolism
MH  - Immunoblotting
MH  - *Mitogen-Activated Protein Kinases
MH  - N-Formylmethionine Leucyl-Phenylalanine/*pharmacology
MH  - Neutrophils/drug effects/*enzymology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Phosphorylation
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Rats
MH  - Type C Phospholipases/antagonists & inhibitors
MH  - p38 Mitogen-Activated Protein Kinases
EDAT- 2000/03/10 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/03/10 09:00
PHST- 2000/03/10 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/03/10 09:00 [entrez]
AID - S0014-2999(00)00033-9 [pii]
AID - 10.1016/s0014-2999(00)00033-9 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2000 Feb 25;390(1-2):61-6. doi: 10.1016/s0014-2999(00)00033-9.